AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PST). The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will discuss the company's Q2 2025 financial and business results.
The webinar will include a Q&A session, with participants able to submit questions through the registration page. A replay will be made available on AVITA Medical's investor relations website after the event.
AVITA Medical (NASDAQ: RCEL) reported Q2 2025 financial results with commercial revenue of $18.4 million, up 21% year-over-year, despite facing significant headwinds. The company reported a net loss of $9.9 million ($0.38 per share), an improvement from $15.4 million loss in Q2 2024.
Key developments include Medicare Administrative Contractor (MAC) payment delays affecting RECELL® System demand, leading to revised full-year 2025 revenue guidance of $76-81 million, down from $100-106 million. The company amended credit terms with OrbiMed, lowering revenue covenants and issuing stock instead of cash payment.
Clinical highlights show RECELL reducing hospital stays by 36%, and CMS approval of New Technology Add-on Payment for trauma wounds. The company now expects to reach cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026.
AVITA Medical (NASDAQ: RCEL) has announced significant changes to its Board of Directors. Dr. Michael Tarnoff, MD, FACS has been appointed as a non-executive Director effective August 6, 2025, bringing extensive executive and medical leadership experience from Tufts Medical Center and Medtronic.
Additionally, the company announced a leadership transition where Cary Vance will succeed Lou Panaccio as Board Chair effective August 7, 2025. Panaccio steps down after more than 10 years of service. The changes come as AVITA Medical strengthens its focus on advancing patient-centric wound-healing technologies and expanding its presence across healthcare settings.
AVITA Medical (NASDAQ: RCEL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time).
Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website. To join via telephone, participants must pre-register to receive dial-in details and a personal PIN. A replay will be available on the company's Investor Relations website after the event.
AVITA Medical (NASDAQ: RCEL) is hosting its virtual Acute Wound Care Showcase 2025 on May 13, 2025, at 11:00 a.m. Pacific Time. The event will feature presentations from leading burn and trauma clinicians using AVITA's technologies, alongside patient testimonials about their treatment experiences with the company's solutions.
CEO Jim Corbett and SVP of Scientific and Medical Affairs Dr. Katie Bush will present AVITA's integrated approach to acute wound care, highlighting key technologies including RECELL®, Cohealyx™, and PermeaDerm®. The showcase will include a live Q&A session, with registration available through the company's website. A replay will be accessible from May 14 on AVITA Medical's Investor Relations site.
AVITA Medical (NASDAQ: RCEL) has announced its inaugural Acute Wound Care Showcase 2025, scheduled for May 13, 2025, at 11:00 a.m. Pacific Time via webcast. The event will feature presentations from CEO Jim Corbett and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs.
The showcase will highlight AVITA Medical's comprehensive approach to acute wound care, featuring their product portfolio including RECELL®, Cohealyx™, and PermeaDerm®. Attendees will gain insights through physician testimonials and, for the first time, hear directly from patients whose lives have been transformed by these technologies.
The event will demonstrate the clinical and economic benefits of AVITA's technologies and conclude with a live Q&A session. Interested parties can register through the Events & Presentations section of AVITA Medical's Investor Relations website, with a replay available the following day.